GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Intrinsic Value: Projected FCF

Sandoz Group AG (Sandoz Group AG) Intrinsic Value: Projected FCF : $0.00 (As of May. 25, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-25), Sandoz Group AG's Intrinsic Value: Projected FCF is $0.00. The stock price of Sandoz Group AG is $34.995. Therefore, Sandoz Group AG's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Sandoz Group AG's Intrinsic Value: Projected FCF or its related term are showing as below:

SDZNY's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.57
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Sandoz Group AG Intrinsic Value: Projected FCF Historical Data

The historical data trend for Sandoz Group AG's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Intrinsic Value: Projected FCF Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Intrinsic Value: Projected FCF
- -

Sandoz Group AG Quarterly Data
Dec22 Dec23
Intrinsic Value: Projected FCF - -

Competitive Comparison of Sandoz Group AG's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Price-to-Projected-FCF falls into.



Sandoz Group AG Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Sandoz Group AG  (OTCPK:SDZNY) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Sandoz Group AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=34.995/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sandoz Group AG Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG (Sandoz Group AG) Business Description

Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024